NCOA Outstanding Fellow Recognition

The North Carolina Oncology Association (NCOA) is proud to showcase the following fellows—and recipients of the NCOA Outstanding Fellow Recognition— for their important contributions to cancer care and their communities.

  • NCOA-Outstanding-Fellow-Recognition-Venkata-175x135
    Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant

    Pavan Kumar Tenneti Venkata, MD, et al., Levine Cancer Institute, Charlotte, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Faisal-175x135
    ADAMTS13 Inhibitor as a Marker for Recurrence of Acquired Thrombotic Thrombocytopenic Purpura

    Annum Faisal, MD, et al., East Carolina University, Greenville, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Jensen-175x135
    Bone Health in Chronic Lymphocytic Leukemia

    Heather Wolfe, MD, et al., Duke University School of Medicine, Durham, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Kamboj-175x135
    Exploring the Role of PCSK9 in Regulating an Immune Excluded Microenvironment and Resistance to Immune Checkpoint Blockade in NSCLC

    James Isaacs, MD, et al., Duke University School of Medicine, Durham, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Benefield-175x135
    Immunotherapy Experience in Nonagenarian Veterans with Cancer

    Andrew Benefield, MD, et al., Wake Forest School of Medicine, Winston-Salem, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Amara-175x135
    Impact of COVID-19 Pandemic on Cancer Screening in Eastern North Carolina

    Sukriti Kamboj, MD, et al., East Carolina University, Greenville, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Margalski-175x135
    Machine Learning for Prospective Identification of Immunotherapy Related Adverse Events

    Dan Margalski, DO, et al., Wake Forest School of Medicine, Winston-Salem, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Pallas-175x135
    Observed Survival Benefit with Limited Exposure of Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer at a Large Community-Based Institution

    Christopher R. Pallas, MD, et al., Levine Cancer Institute, Charlotte, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Wofford-175x135
    Outcomes Associated with BEAM Conditioning Followed by Autologous Stem Cell Transplant in High-Risk Geriatric Patients

    Anne Wofford, MD, et al., Wake Forest School of Medicine, Winston-Salem, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Amara-175x135
    Peripheral Blood T Cell Responses to Immunotherapy Related Adverse Events in NSCLC Patients Treated with Immunotherapy

    Suneetha Amara et al., East Carolina University, Greenville, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Jensen-175x135
    Prevalence of Functional Deficits Among Adults with Multiple Myeloma and Normal Perceived Performance Status

    Christopher Jensen, MD, et al., University of North Carolina School of Medicine, Chapel Hill, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Gaddy-175x135
    Racial Differences in Impact of Geography on Breast Cancer Treatment Delay

    Jacquelyne Gaddy, MD, et al., University of North Carolina School of Medicine, Chapel Hill, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Morgan-175x135
    Real-World Curative-Intent Treatment Patterns for Breast Cancer in an HIV-prevalent Malawian Cohort

    Jennifer Morgan, MD, et al., University of North Carolina School of Medicine, Chapel Hill, NC
    View Poster

  • NCOA-Outstanding-Fellow-Recognition-Young-175x135
    Survival Outcomes with the Use of Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer at a Large Hybrid Cancer Institute

    Joanna A. Young, DO, et al., Levine Cancer Institute, Charlotte, NC
    View Poster


1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
ncoa-northcarolina.com
Email Us